Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF
The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.

Hoạt chất mới

2 New

Chỉ định mới

1 New

Biệt dược mới

1 New

Ký hiệu trên viên thuốc
Hình dạng
Dạng
Màu 1
Màu 2
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in